Authors
Ryusuke Ae, Koki Kosami, Hiroya Masuda, Naoto Kato, Takahide Kohro, Mitsuru Seki, Yoshihide Shibata, Tohru Kobayashi, Masanari Kuwabara
Published in
JAMA network open. Volume 9. Issue 8. Pages e2626910. Aug 03, 2026. Epub Aug 03, 2026.
Abstract
The COVID-19 pandemic may serve as a natural experiment, with pandemic-associated changes in the epidemiology of Kawasaki disease (KD) potentially informing understanding of KD pathogenesis.
To assess long-term KD incidence across 50 years and to examine pandemic-associated changes in KD epidemiology across age groups.
This cohort study was a descriptive epidemiologic analysis of data from the Japanese Nationwide Survey of Kawasaki Disease conducted from 2023 to 2024, along with 50 years of historical data. Data were included from patients with KD in the current 2023-2024 survey (n = 29 841) and historical and current survey data from 1975 through 2024 (n = 467 456) for trend analysis.
Annual KD incidence overall and stratified by 3 age groups: infants (<1 year), 1 to 4 years, and 5 to 9 years.
The current survey registered 15 032 and 14 809 patients with KD in 2023 and 2024, respectively (overall, 57.3% male; median [IQR] age, 2 [1-4] years). Across the 50-year study period, despite the population under 5 years of age declining in Japan by 61.6%, KD incidence rates increased 16.1-fold. Across the COVID-19 pandemic period, patient numbers reached a nadir of 10 333 in 2022, then rebounded to 15 032 cases (45.5% increase) in 2023. Notably, decline and rebound patterns differed by age. Indexed incidence rates (using 2017 as a baseline of 100) demonstrated that patients 5 to 9 years of age had the largest decline (nadir of 54.2 in 2021, 45.8% below baseline) and the largest rebound (134.8 in 2024, 34.8% above baseline). In contrast, patients younger than 1 year showed the smallest decline (nadir of 73) and incidence rates did not return to baseline levels. When comparing the magnitude of rebound in KD incidence, a distinct age-dependent dose-response pattern was observed: 26.1% for infants, 38.9% for patients aged 1 year, 42.7% for patients aged 2 years, 85.8% for patients aged 3 years, 105.3% for patients aged 4 years, and 166.7% for patients aged 5 to 9 years.
In this nationwide cohort study of KD in Japan, KD incidence rebounded after the relaxation of COVID-19 pandemic-related restrictions, with age-dependent patterns. Nonpharmaceutical interventions (eg, mask-wearing) during the pandemic may explain the greater rebound pattern observed in older children; however, the minimal changes in infants suggest different exposure pathways to potential KD triggers. These findings support an age-stratified approach to KD pathogenesis research, distinguishing infants from older children.
PMID:
42550508
Bibliographic data and abstract were imported from PubMed on 04 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 33
- Comments 0